Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials. - Zhou DD; Lord SJ; Lin FP; Cooper WA; Zaheed M; Simes RJ; John T; Lee CK (Lung cancer (Amsterdam, Netherlands), 2026)